Pharmacological treatment of depression in people with a primary brain tumour
- 17 July 2020
- journal article
- review article
- Published by Wiley in Emergencias
- Vol. 2020 (7), CD006932
- https://doi.org/10.1002/14651858.cd006932.pub4
Abstract
Background This is the second updated version of the Cochrane Review published in Issue 3, 2010 and first updated in Issue 5, 2013. People with a primary brain tumour often experience depression, for which drug treatment may be prescribed. However, they are also at high risk of epileptic seizures, cognitive impairment, and fatigue, all of which are potential adverse side effects of antidepressants. The benefit, or harm, of pharmacological treatment of depression in people with a primary brain tumour is unclear. Objectives To assess the benefits and harms of pharmacological treatment of depression in people with a primary brain tumour. Search methods We updated the search to include CENTRAL, MEDLINE, Embase, and PsycINFO to September 2019. As in the original review, we also handsearched Neuro‐Oncology, Journal of Neuro‐Oncology, Journal of Neurology, Neurosurgery and Psychiatry, and Journal of Clinical Oncology: for the current update we handsearched the latest three years of articles from these journals (up to November 2019). Selection criteria We searched for all randomised controlled trials (RCTs), controlled clinical trials, cohort studies, and case‐control studies of any pharmacological treatment of depression in people with a histologically diagnosed primary brain tumour. Data collection and analysis No studies met the inclusion criteria. Main results We found no eligible studies evaluating the benefits of any pharmacological treatment of depression in people with a primary brain tumour. Authors' conclusions We identified no high‐quality studies that investigated the value of pharmacological treatment of depression in people with a primary brain tumour. RCTs and detailed prospective studies are required to inform the effective pharmacological treatment of this common and important complication of brain tumours. Since the last version of this review none of the related new literature has provided additional information to change these conclusions.Keywords
This publication has 68 references indexed in Scilit:
- Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II–IVJournal of Neuro-Oncology, 2018
- The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trialNeuro-Oncology, 2013
- Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and moodJournal of Neuro-Oncology, 2012
- A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumorJournal of Neuro-Oncology, 2011
- Selective Serotonin Reuptake Inhibitors, Glioblastoma Multiforme, and Impact on Toxicities and Overall SurvivalAmerican Journal of Clinical Oncology, 2011
- A Pilot Study Evaluating the Safety and Efficacy of Modafinil for Cancer-Related FatigueJournal of Palliative Medicine, 2009
- Pilot Study: Fluvoxamine Treatment for Depression and Anxiety Disorders in Children and Adolescents with CancerJournal of the American Academy of Child & Adolescent Psychiatry, 2005
- Depression in Patients with High-grade Glioma: Results of the Glioma Outcomes ProjectNeurosurgery, 2004
- Differential Effects of Paroxetine on Fatigue and Depression: A Randomized, Double-Blind Trial From the University of Rochester Cancer Center Community Clinical Oncology ProgramJournal of Clinical Oncology, 2003
- Methylphenidate therapy improves cognition, mood, and function of brain tumor patients.Journal of Clinical Oncology, 1998